Curriculum · Nephrology and Urology
Chronic kidney disease
What it is
Chronic kidney disease is an abnormality of kidney structure or function that is present for 3 or more months. The tubules atrophy and the interstitial tissue undergoes fibrosis. On imaging the kidneys are small. Chronic kidney disease is the most common cause of small kidneys and is the final common pathway of many chronic conditions; the other named cause of small kidneys is chronic glomerulonephritis, which leads to scarring and atrophy.
How it presents
What is felt first is often the anemia: fatiguability and decreased exercise tolerance. Nausea and vomiting are the clinical signs that matter in uremia. Salt and water retention shows as systemic volume overload, with hypertension and pitting edema.
How it is diagnosed
The diagnosis rests on a persistent impaired creatinine clearance, not on one reading. To take a described example, an eGFR of 39 mL/min/1.73 m2 that stays low over 8 months in an older patient with longstanding hypertension and dyslipidemia is what is meant by persistent.
The biochemical profile of untreated disease is a low calcium with a high phosphate, a high PTH and a high ALP. The route to it: the fall in glomerular filtration reduces renal excretion of phosphate, the phosphate that remains binds ionized calcium, calcium in the blood falls, the inhibition of PTH release falls with it, and PTH in the blood rises.
How it is treated
Each complication has its own answer.
- Sodium retention and volume overload: sodium restriction and diuretics.
- Hyperkalemia: dietary restriction, and avoid NSAIDs.
- Metabolic acidosis: sodium bicarbonate.
- High phosphate, high PTH, low serum calcium and low calcitriol: phosphate binders and calcimimetics.
- Anemia: erythropoiesis-stimulating agents with iron replacement.
Dialysis stands at the end of that line, for the uremia.
The mineral and bone disorder has a ladder of its own, and the goal is to normalize phosphate, calcium and PTH levels. Hyperphosphatemia is treated by dietary phosphate restriction and by phosphate binders such as sevelamer. Hyperparathyroidism is treated by cholecalciferol or ergocalciferol supplementation where vitamin D is deficient or insufficient, and by parathyroidectomy, which is last-line therapy. So a patient whose PTH stays high in spite of the restriction, the binder and the vitamin D has already been through the earlier rungs, and what is left is the parathyroidectomy.
Referral has a number of its own, and the GFR categories are counted, not just named. The national guideline gives them as stages by eGFR in ml/min/1.73m2:
- Stage 1, G1: kidney damage with normal or increased GFR, 90 or above
- Stage 2, G2: kidney damage with mildly decreased GFR, 60-89
- Stage 3a, G3a: mildly to moderately decreased GFR, 45-59
- Stage 3b, G3b: moderately to severely decreased GFR, 30-44
Stage 4, G4: severely decreased GFR, 15-29. Stage 5, G5: kidney failure, below 15 or on dialysis. The rule is to refer to a nephrologist and prepare for kidney replacement therapy when GFR is below 30 mL/min/1.73m. In the absence of evidence of kidney damage, neither GFR category G1 nor G2, that is stage 1 or stage 2, fulfils the criteria for CKD at all.
There are also referrals that do not wait for that number: uncertainty about the aetiology of the kidney disease; pre-existing renal disease with hypertension; worsening proteinuria or albuminuria in spite of medical therapy, that is a rapid worsening of renal function with a drop in eGFR of 25% or more from baseline or a sustained decline of more than 5ml/min/1.73m2 per year; hematuria and proteinuria with or without renal impairment in the absence of urological causes; side effects of ACE inhibitors or ARBs such as persistent hyperkalaemia; and a small kidney size on renal ultrasound. A drop in eGFR of 25% or more from baseline meets that criterion on its own.
The same guideline sets the monitoring by eGFR band. All patients have a yearly measurement of creatinine, urinary albumin excretion and potassium. At an eGFR of 45-60: referral to nephrology if there is a possibility of non-diabetic kidney disease, that is type 1 diabetes of duration less than 10 years, heavy proteinuria, abnormal findings on renal ultrasound, resistant hypertension, a rapid fall in eGFR, or active urinary sediment; consider the need for medication dose adjustment; monitor eGFR every 6 months; monitor electrolytes, bicarbonate, haemoglobin, calcium, phosphorus and parathyroid hormone at least yearly; exclude vitamin D deficiency; consider bone density testing; and refer for dietary counselling. At an eGFR of 30-44: monitor eGFR every 3 months; monitor electrolytes, bicarbonate, calcium, phosphorus, parathyroid hormone, haemoglobin, albumin and weight every 3-6 months; and consider the need for medication dose adjustment. At an eGFR of 30 or lower: referral to the nephrologist.
Where the kidney disease sits alongside diabetes, the blood pressure is treated to a target and the drug groups are named. Hypertension is defined as a blood pressure of 140/90mmHg or above, diagnosed on at least two or three separate occasions one to two weeks apart, and the aim is 130/80 or below in patients less than 65 years of age and those at high risk for CVD, and below 140/80 in elderly patients of 65 years or more if tolerated. Initial treatment may be an ACE inhibitor, an ARB, a thiazide-like diuretic or a dihydropyridine calcium channel blocker, and for patients with persistent albuminuria it should include a RAS blocker, though ACE inhibitors and angiotensin receptor blockers are not combined. Pregnancy rules that whole group out: in pregnant women with diabetes and chronic hypertension the suggested target is 120-135/80-85 mmHg, and ACE inhibitors and ARBs are contraindicated during pregnancy. So the ACE inhibitor is stopped, and an ARB is no way round it, since the ARBs are contraindicated too.
One slide puts the whole regimen into five lines, each with its own number beside it. Blood pressure control below 130/80: give an ACE inhibitor. BG 80-110: give insulin. Hypertension and electrolytes: a diet low in Na+ and K+. Hgb between 11 and 12: give EPO and iron. And give calcium and vitamin D, to avoid secondary hyperparathyroidism. So the anemia here is not treated with iron alone nor with EPO alone; the two are given together, and the Hgb band that calls for them is 11 to 12.
The anemia has an order to it, and iron comes first. In a 59 year old woman evaluated for fatigue and weakness, with chronic kidney disease and hypertension, taking only amlodipine, whose blood pressure is 151/96 mm Hg, with conjunctival pallor and no scleral icterus, and whose studies show a hemoglobin of 7.9 g/L, an MCV of 80 fL, a ferritin of 24 ng/mL, a transferrin saturation of 10% and an eGFR of 18 mL/min/1.73m2, the most appropriate treatment is iron supplementation, not blood transfusion, not an erythropoietin-stimulating agent and not a bone marrow biopsy. The low ferritin and the low transferrin saturation are what place iron first.
The phosphate has an order of its own. Hyperphosphatemia is an early manifestation of chronic kidney disease and starts to appear when the estimated glomerular filtration rate is decreased to 25 to 40 mL/min; it is associated with increased cardiovascular risk and with increased morbidity and mortality, and it is itself a stimulus for hyperparathyroidism. Dietary restriction of phosphate is the first initial step if the phosphate is only mildly elevated, and a phosphate binder is used only if the phosphate is persistently and progressively elevated despite dietary phosphorus restriction. So the answer to a mildly raised phosphate is to restrict dietary phosphorus intake, and not oral calcitriol, not more dietary calcium, not oral calcium carbonate, and not restriction of dietary calcium.
Where the kidney disease sits on top of type 2 diabetes, the second-line drug is chosen by the comorbidity, and chronic kidney disease takes an SGLT2 inhibitor because it slows progression of CKD. The rest of that choice runs: atherosclerotic CVD takes a GLP-1 RA, for example liraglutide, or an SGLT2 inhibitor, for proven CV benefit; heart failure takes an SGLT2 inhibitor, which reduces hospitalizations and CV mortality; a need to avoid hypoglycemia takes a DPP-4 inhibitor, a GLP-1 RA or an SGLT2 inhibitor, for the safe profile; a desire for weight loss takes a GLP-1 RA or an SGLT2 inhibitor; and where cost is a concern, a sulfonylurea such as gliclazide, or metformin, which are inexpensive and effective.